Zogenix (ZGNX) Gets a Buy Rating from Mizuho Securities

By Jason Carr

Mizuho Securities analyst Difei Yang maintained a Buy rating on Zogenix (ZGNXResearch Report) today and set a price target of $65.00. The company’s shares closed last Monday at $42.41.

According to TipRanks.com, Yang is a 3-star analyst with an average return of 2.9% and a 37.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Alder Biopharmaceuticals, and Audentes Therapeutics.

Currently, the analyst consensus on Zogenix is a Strong Buy with an average price target of $64.00, representing a 49.6% upside. In a report released today, Northland Securities also maintained a Buy rating on the stock with a $60.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $56.50 and a one-year low of $33.43. Currently, Zogenix has an average volume of 575K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.